Alzheimer’s disease is one of the most complex and debilitating neurological disorders that affect people every day. It slowly damages memory, thinking, and behavior, making everyday tasks increasingly difficult for those who live with it. For decades, scientists have mainly focused on genetics and finding traces of abnormal proteins in the brain to diagnose the disease. According to the Alzheimer’s Association, Alzheimer’s is the most common cause of dementia. New research suggests that infections may also play a role in the disease’s development.
A recent study reported by Medical News Today explored the role of a common bacterium called Chlamydia pneumoniae, which is typically connected with respiratory diseases such as pneumonia. Researchers looked at eye tissues from over 100 individuals and discovered higher levels of Chlamydia pneumoniae in people with Alzheimer’s compared to those without the disease. According to Medical News Today, scientists noted that bacterial presence appeared to “track with disease severity,” meaning that higher levels of infection were associated with more advanced stages of cognitive decline. This apparent link is supported by research from the National Institutes of Health, which has explored how infections and inflammation may contribute to neurodegenerative diseases.
Another important discovery from the same study reported by Medical News Today involved amyloid-beta, a protein recognized as a defining feature of Alzheimer’s disease. The study found that infection with Chlamydia pneumoniae was connected with increased production of amyloid-beta. Amyloid-beta is a sticky protein fragment that naturally forms in the brain, but in Alzheimer’s patients, it builds up abnormally and clumps together into plaques. These plaques block communication between nerve cells and trigger inflammation, eventually leading to brain cell death and memory loss. According to the National Institute on Aging, amyloid-beta buildup is a defining characteristic of Alzheimer’s disease. Because of the connection between bacterial infection and amyloid-beta buildup, researchers are exploring how environmental factors, such as infections, may interact with biological processes to influence disease development.
Genetics may also play a role in how bacterial infections affect Alzheimer’s risk. In the same study reported by Medical News Today, researchers observed that individuals who carried the APOE4 gene variant, which is already known to increase the risk of developing Alzheimer’s, tended to have higher levels of Chlamydia pneumoniae in their eye and brain tissue. According to the National Institute on Aging, APOE4 is the strongest known genetic risk factor for a late-onset of Alzheimer’s disease. This suggests that certain individuals may be more vulnerable to infection due to their genetic makeup. Understanding how genetic predisposition and environmental influences interact can help scientists develop more personalized strategies for prevention and treatment.
One of the most experimental aspects of this research involves the retina, which is part of the nervous system and may reflect changes occurring in the brain. Scientists believe that the retina could potentially serve as a window into early neurological changes, as reported by Medical News Today. Because the eye is more accessible than the brain, monitoring infection-related inflammation in retinal tissue could one day help with earlier detection. However, this approach is still in the early stages of research and is not currently used in standard medical practice.
At present, Alzheimer’s disease is diagnosed using well-established methods. These include PET brain scans, which detect amyloid plaque buildup, and spinal tap procedures that analyze cerebrospinal fluid for biomarkers associated with the disease. More recently, blood tests that detect abnormal protein accumulation have emerged as a promising and less invasive method for early detection, according to The New York Times. Compared to these approaches, retinal testing is still experimental and requires more research before it can be considered a reliable way of diagnosing Alzheimer’s.
Although retinal detection may hold promise in the future, current diagnostic methods remain centered on brain imaging, spinal fluid analysis, and increasingly, blood-based testing.
